- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Interventions
- SB-007
- Genetic
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 909
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 51 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
- Interventions
- RN6G, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 24
- States / cities
- Campbell, California • Los Gatos, California • San Jose, California + 7 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Implantable Miniature Telescope (IMT)
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 11 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SB15 (Proposed aflibercept biosimilar), Eylea (Aflibercept)
- Drug
- Lead sponsor
- Samsung Bioepis Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Chevy Chase, Maryland • Abilene, Texas
- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 91
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
- Interventions
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Westport, Connecticut
- Conditions
- Macular Degeneration
- Interventions
- MSI-1256F (Squalamine Lactate)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Plymouth Meeting, Pennsylvania
- Conditions
- Intravitreal Injection, Ocular Rinse, Age-Related Macular Degeneration, Diabetic Macular Edema, Cystoid Macular Edema
- Interventions
- OSDI questionnaire, SPEEDII questionnaire
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- CYSTOID MACULAR EDEMA
- Interventions
- Ranibizumab,, Triamcinolone acetonide
- Drug
- Lead sponsor
- Soll Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Retinitis Pigmentosa, AMD
- Interventions
- Rod sensitivity
- Diagnostic Test
- Lead sponsor
- Retina Foundation of the Southwest
- Other
- Eligibility
- 10 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Nonexudative Age-related Macular Degeneration
- Interventions
- MC-1101, Placebo
- Drug
- Lead sponsor
- MacuCLEAR, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
- Interventions
- ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
- Drug · Other
- Lead sponsor
- ONL Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 56
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more
- Conditions
- Macular Degeneration
- Interventions
- GW786034, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
- Conditions
- Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
- Interventions
- OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
- Dietary Supplement
- Lead sponsor
- Western University of Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Pomona, California
- Conditions
- Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
- Interventions
- DS-7080a, Ranibizumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 9 more
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
- Interventions
- CD34+ bone marrow stem cells intravitreal
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
- Interventions
- Biological Sample Collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 30 Days and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2045
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration
- Interventions
- Emixustat HCl Tablet, Placebo Tablet
- Drug · Other
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neovascular Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more